

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : A61K 31/15, 9/10	A1	(11) International Publication Number: WO 99/16454 (43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/GB98/02899 (22) International Filing Date: 25 September 1998 (25.09.98) (30) Priority Data: 9720590.0 26 September 1997 (26.09.97) GB 9725346.2 28 November 1997 (28.11.97) GB (71) Applicant (for all designated States except US): MEDEVA EUROPE LIMITED (GB/GB); 10 St. James's Street, London SW1A 1BP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SACHETTO, Jean-Pierre (FR/CH); Duchscher 13, CH-4051 Basel (CH). SAND-BORN, William, Jeffery (US/US); 1132-7th Street, S.W., Rochester, MN 55902 (US). TREMAINE, William, John (US/US); 625 Memorial Parkway, S.W., Rochester, MN 55905 (US). (74) Agent: BURFORD, Anthony, F.; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (57) Abstract A polysaccharide selected from xanthan gum and HPMC is used for the treatment or prophylaxis of IBD, especially Crohn's Disease, left-sided ulcerative colitis or pouchitis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT
OF INFLAMMATORY BOWEL DISEASE

This invention relates to use of xanthan gum or
5 hydroxypropylmethylcellulose (HPMC), particularly in the
form of enemas for the treatment of inflammatory bowel
disease (IBD), and to orally administrable and
rectally/vaginally administrable compositions containing
xanthan gum or HPMC as a therapeutically active agent.

10 Xanthan gum (CAS registry no. 1138-66-2) is described
in USP NF XVI (p161) as a high molecular weight
polysaccharide gum produced by a pure-culture fermentation
of a carbohydrate with *Xanthomonas campestris*. It contains
15 D-glucose and D-mannose as the dominant hexose units, along
with D-glucuronic acid and is prepared as the sodium,
potassium or calcium salt. It is widely used in
pharmaceutical compositions as an emulsifying, stabilising
and/or thickening agent.

20 HPMC (CAS registry no. 9004-65-3), otherwise known as
hypromellose, is used as a suspending agent, tablet
excipient, demulcent and/or viscosity increasing agent in
pharmaceutical compositions. It is been used as a capsule
25 or tablet coating, but the coating is soluble in gastric
juices, and so would deliver the active in the capsule in
the stomach.

IBD covers chronic non-specific inflammatory conditions
30 of the gastro-intestinal tract, of which the two major forms
are Crohn's disease and ulcerative colitis. The aetiology
of these diseases is uncertain. Many inflammatory mediators
have been proposed including prostanoids, leukotrienes,
platelet activating factor, cytokines, and free oxygen
35 radicals. Although specific inhibitors of most of these
have been tried in experimental models, the most effective
drugs currently available for these diseases have a broad
activity against inflammatory processes.

Crohn's disease is characterised by thickened areas of the gastro-intestinal wall, with inflammation extending through all layers, deep ulceration and fissuring of the mucosa, and the presence of granulomas. Affected areas may occur in any part of the gastro-intestinal tract, although the terminal ileum is frequently involved, and they may be interspersed with areas of relatively normal tissue. Fistulas and abscesses may develop. Symptoms depend on the site of disease but may include abdominal pain, diarrhoea, fever, weight loss and rectal bleeding.

In ulcerative colitis, disease is continued to the colon and rectum. Inflammation is superficial but continuous over the affected area and granulomas are rare. In mild disease, the rectum alone may be affected (proctitis). In severe disease ulceration is extensive and much of the mucosa may be lost, with an increased risk of toxic dilatation of the colon, a potentially life-threatening complication.

Abdominal colectomy with mucosal proctectomy and ileal pouch-anal anastomosis is the preferred treatment for most patients with ulcerative colitis who require surgery. Pouchitis, the most common long-term complication of the procedure, occurs in up to 49% of patients at 10 years. Chronic pouchitis is distinguished from acute pouchitis by duration of symptoms for more than 4 weeks. The aetiology of pouchitis is unknown but it appears that both a history of ulcerative colitis and increased bacterial concentrations (relative to the normal ileum) are factors.

Currently, there is no satisfactory treatment for patients with chronic pouchitis who fail to respond to empiric antibiotic therapy. Although metronidazole is effective in some patients, long-term use is limited by concerns for neurotoxicity with peripheral neuropathy.

Numerous compounds have been examined in the last twenty years to find effective measures for the treatment of IBD. Such compounds include azathioprine, arsenicals, disodium cromoglycate, metronidazole, lignocaine, 5-aminosalicylic acid (5-ASA), fish oils, thalidomide and cyclosporin. The wide diversity of treatments, is an indication of the complexity and intransigence of IBD.

GB-A-1538133 (published 8th January 1979) disclosed the treatment of diverticulitis with a fibrous cellulosic material and a carboxylic polymer or salt which absorbs water and swells above pH 4. Specified carboxylic polymers include sodium carboxymethylcellulose (sodium CMC).

EP-A-0351987 (published 24th January 1990) disclosed the use of a polyacrylate, preferably a carbomer, for the treatment of IBD by oral or rectal administration.

US-A-4917890 (published 17th April 1990) disclosed the treatment of ulcerative colitis with a mucilaginous polysaccharide also extract.

WO-A-94/01436 (published 3rd March 1994; corresponding to US-A-5386532) disclosed treatment of irritable bowel syndrome (IBS) with an oral medicament of an anion-binding polymer and a hydrophilic polymer. Exemplified anion-binding polymers include xanthan gum.

WO-A-9407540 (published 14th April 1994; corresponding to EP-A-0620012 & US-A-5518711) disclosed an X-ray contrast medium containing 15-35 w/v% BaSO₄ and 0.15-0.6 w/v% xanthan gum dispersed in water. Lower xanthan gum concentrations are used with higher BaSO₄ concentrations. The medium is useful for double contrast enema examination of the large and the small intestine to detect inter alia Crohn's disease.

Sandborn et al (Gastroenterology 1994, 106, 1429-1435) reported a placebo-controlled trial of cyclosporin enemas in the treatment of mildly to moderately active left-sided ulcerative colitis. The vehicle for both the test and placebo enemas comprised 60 cm³ water, 5 mg sorbitol (to make the vehicle isomolar) and 500 mg carboxymethylcellulose (CMC) (to suspend the hydrophobic cyclosporin). The placebo enema contained 3.5 cm³ olive oil and use of this enema resulted in clinical improvement in nine out of twenty patients tested.

WO-A-9603115 (published 8th February 1996) disclosed aqueous foamable compositions having a delayed foaming action on expulsion from a pressurised container, comprising a water-immiscible liquefied gas, a water soluble polymer, and optionally, inter alia, a muco-adhesive agent. Exemplified water-soluble polymers include xanthan gum and HPMC and exemplified muco-adhesive agents include CMC. The compositions are of particular use for rectal or vaginal administration of pharmaceuticals to treat inter alia ulcerative colitis or Crohn's disease.

JP-A-08198757 (published 6th August 1996) discloses the use of high amylose starch, preferably administered with food materials, for the treatment of chronic ulcerative colitis.

The present Inventors found that xanthan gum and HPMC are effective *per se* for the treatment of IBD. This is surprising because, as indicated above, these materials are widely used in pharmaceutical compositions because of their assumed lack of pharmacological activity.

WO 98/01112 (published 15th January 1998; after the claimed priority dates of the present Application) discloses the treatment of distal IBD with a hydrogel formulation consisting essentially of a gelling agent and water with the optional presence of a pH-adjusting agent, plasticizer

and/or surfactant. The preferred gelling agents include HPMC and sodium CMC. The only specified distal IBD is ulcerative colitis.

5 According to a first aspect of the present invention, there is provided the use of a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.

10

By IBD we mean Crohn's Disease and ulcerative colitis including ulcerative proctitis, ulcerative proctosigmoiditis, lymphocytic colitis, intractable distal colitis, ileocolitis, collagenous colitis, microscopic
15 colitis, pouchitis, radiation colitis, and antibiotic-associated colitis. Xanthane gum and HPMC have been found to be particularly useful in the treatment of IBD conditions (such as pouchitis and left-sided ulcerative colitis) normally refractive to conventional therapy.

20

In a second aspect, the present invention provides a post-gastrically available delayed release oral (DRO) or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising
25 a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in an amount effective to treat IBD, together with a pharmaceutically acceptable carrier or vehicle. DRO compositions pass through the stomach substantially unaltered and deliver their active ingredient
30 (which is within the tablet, capsule etc.) typically to the ileum up to and including the colon (i.e. where the diseased mucosa is).

According to a third aspect, the present invention
35 provides a post-gastrically available DRO or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as the

sole therapeutically active agent together with a pharmaceutically acceptable carrier or vehicle.

5 In a fourth aspect, the present invention provides the use of a polysaccharide selected from xanthan gum and HPMC as the sole therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.

10 In yet another aspect of the present invention, there is provided a method for the treatment or prophylaxis of IBD comprising contacting the diseased mucosa of the gastrointestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and HPMC.

15 The polysaccharide can be used in the form of pharmaceutically acceptable salts of such as with alkali metals, usually sodium or potassium and alkaline earth metals, usually calcium or barium.

20 When the polysaccharide is present as the sole active agent, then no other therapeutically active agent such as 5-ASA or a corticosteroid will be present. Optionally, however, other therapeutic agents currently used or proposed for treating IBD can also be used sequentially in a
25 different dosage form or concomitantly in the same dosage form as the polysaccharide. Examples of other such therapeutic agents are 5-ASA; immune modifiers such as azathioprine, cyclosporin and FK506; corticosteroids such as prednisolone, budesonide and hydrocortisone; antibiotics
30 such as metronidazole, ciprofloxacin, amoxicillin, tetracycline and sulphamethoxazole; antidiarrheals such as loperamide and codeine sulphate; and local anaesthetics such as lignocaine.

35 The polysaccharide may be incorporated into a pharmaceutical composition to be administered either rectally, e.g. as an enema, or orally, for example, in coated tablets or capsules as described below. Also, the

polysaccharide may be formed into microgranules and coated, for example with Eudragit™ L or S and contained within a capsule similarly coated. In all solid compositions, it is preferable to include a disintegrant. Still further, the polysaccharide may be formulated in a number of dosage forms, e.g. uncoated or coated solid dosage forms for delayed release oral administration, for example using polymers in the Eudragit™ product range.

10 According to a preferred embodiment of the present invention, the pharmaceutical composition takes the form of an enema formulation such as a liquid or foam enema which is rectally administered to the lower colon. The enema formulations suitably comprise the polysaccharide dissolved
15 or dispersed in a suitable flowable carrier vehicle, such as deionised and/or distilled water. The formulation can be thickened with one or more thickeners, can contain a buffer, and can also comprise an effective amount of a lubricant such as a natural or synthetic fat or oil, e.g. a tris-fatty
20 acid glycerate or lecithin. Non-toxic non-ionic surfactants can also be included as wetting agents and dispersants. Unit doses of enema formulations can be administered from pre-filled bags or syringes. In the case of a pressurised enema formulation the carrier vehicle may also comprise an
25 effective amount of a foaming agent such as n-butane, propane or i-butane, or the foaming agent/propellant could be held separately from the composition such as in a bag-in-bag or bag-in-can system as described in WO-A-9603115 (incorporated herein by reference). Enema foams may also
30 comprise expanding agents and foam-stabilisers.

The viscosity of the enema is preferably 10,000 to 70,000 mPa.s more preferably 10,000 to 70,000 mPa.s and most preferably 10,000 to 40,000 mPa.s. The pH is preferably 3.5
35 to 7.5, especially 6.5 to 7.5.

A suitable dosage for xanthan gum in an enema or foam enema is 200 to 2000 mg, preferably 250 to 2000 mg, more

preferably 250 to 1650 mg, more preferably still 400 to 1650 mg, especially 550 to 1000 mg, in an aqueous or non-aqueous carrier. The volume of a liquid enema is typically 50 to 200 cm³ preferably about 100 cm³. A suitable % w/w of xanthan gum in an enema is (based on 100 cm³ enema) is 0.2% to 2% w/w, more preferably 0.3% to 2% w/w, more preferably still 0.4% to 2% w/w, more preferably still up to 1.65% w/w, and still more preferably 0.55% to 1%. Suitably the volume of a foam enema is 20 to 40 cm³. Based on the above preferred dosages, a suitable % w/w of xanthan gum in a foam enema (based on 40 cm³ foam enema) is 1% to 4.25% w/w, more preferably 1.4% to 2.5%. A buffer is preferably added to the liquid or foam enema of xanthan gum to stabilise the pH. When a buffer is used it increases the viscosity and as a result, the maximum % w/w of xanthan gum that can be incorporated in the enema is about 1.7% w/w.

Typically the viscosity grade of xanthan gum used in a rectally administrable or DRO composition of the invention is 1,200 to 1,600 cP (mPa.s) at 1%.

Typically the viscosity grade of HPMC used in a rectally administrable or DRO composition of the invention is 3 to 100,000 cP (mPa.s). More particularly the grade of HPMC varies depending on the degree of hydroxypropoxy and methoxy substitution. Thus, preferably the degree of methoxy substitution is 15 to 30%, more preferably 19 to 30% such as 19 to 24% and 27 or 28 to 30%. The degree of hydroxypropoxy substitution is preferably 2 to 15%, more preferably 4 to 12%, such as 7 to 12% or 4 to 7.5%. The commercially available grades of HPMC include the following:

Product	% Methoxyl	% Hydroxypropoxyl	Viscosity cP (Mpa.s)	Relative Rate of Hydration
METHOCEL™ K Premium	19-24	7-12	3, 100, 4000, 15000, 100000	Fastest
METHOCEL™ E Premium	28-30	7-12	3, 5, 6, 15, 50, 4000	Next fastest
METHOCEL™ F Premium	27-30	4-7.5	50, 4000	Slower

The large range of viscosities allows a high dosage liquid enema or foam enema of HPMC to be formed by using a low viscosity grade of HPMC (i.e. a higher dosage than xanthan gum can be incorporated since the viscosity of the HPMC is less limiting). A suitable dosage of HPMC for a liquid enema or foam enema is 0.2 to 20 g, preferably 1 to 20g, more preferably 2 to 10 g, still more preferably 5 to 10 g for some IBD disease states and 1 to 5 g for other IBD disease states. A suitable % w/w of HPMC in a liquid enema or foam enema (based on 100 cm³) is 0.2% to 20% w/w, preferably 1% or 2% w/w to 20%, more preferably to an upper limit of 10% w/w, more preferably still 5% to 10%. A suitable % w/w of HPMC in a foam enema (at 40 cm³) is 1% to 50% w/w, more preferably 2.5% to 25% w/w, such as at least 7.5% w/w.

In a further embodiment of the invention, the polysaccharide is administered to the small intestine or colon of a patient by oral ingestion of a post-gastric delayed release (DRO) unit dosage form such as a tablet or capsule, comprising an effective amount of polysaccharide which is enterically coated so as to be released from the unit dosage form in the lower intestinal tract, e.g. in the

ileum and/or in the colon of the patient. Enteric coatings remain intact in the stomach, but dissolve and release the contents of the dosage form once it reaches the region where the pH is optimal for dissolution for the coating used.

8

A DRO formulation can also be achieved by coating a powder or microgranular formulation of the polysaccharide with coatings as mentioned above. The coated microgranules or material may then be compressed into tablets or packed
10 into hard gelatin capsules suitable for oral administration. Suitable coatings and thicknesses to achieve this sustained release are disclosed in EP-A-0572486 (incorporated herein by reference).

15 The DRO form may optionally also be formulated to give a sustained release of the polysaccharide. The delayed release can be obtained, for example, by complexing the polysaccharide with a polyacrylic acid derivative (a polysaccharide polyacrylate complex) more particularly a
20 polysaccharide carbomer complex. Alternatively particles of the polysaccharide complex could be incorporated into a hydrophobic matrix such as Gelucire™ (Gattefosse, France).

Aqueous film-coating technology is advantageously
25 employed for the enteric coating of pharmaceutical dosage forms. A useful enteric coating is one that remains intact in the low pH of the stomach, but readily dissolves when the optimum dissolution pH of the particular coating is reached. This can vary between pH 3 to 7.5, preferably pH 5 to 7,
30 most preferably pH 5.5 to 6.8, depending on the chemical composition of the enteric coating. The thickness of the coating will depend on the solubility characteristics of the coating material and the site to be treated.

35 By "delayed release" we mean that release is substantially post-gastrically and by "sustained release" we mean that the total release of the polysaccharide is slow

and sustained over a period of time, as opposed to being released as a bolus.

The majority of the release will be targeted to the
5 part of the small intestine or colon where the active
disease is prevalent and this varies for Crohn's disease and
ulcerative colitis. Thus typically for an enteric coated
capsule, the enteric coating should dissolve in the pH of
10 the jejunum (about pH 5.5), ileum (about pH 6) or colon
(about pH 6-7) so as to release the majority of the active
from the jejunum to the colon - where most of the active
disease is located in IBD. More particularly in the case of
Crohn's disease most of the active disease is around the
terminal ileum and so the enteric coating should dissolve
15 about pH 5.5 to 6. In the case of ulcerative colitis, the
disease is mostly in the colon and therefore the enteric
coating should dissolve about pH 6 to 7, more particularly
about pH 6.8.

20 Suitably the unit dosage of the polysaccharide in the
delayed release oral composition is 200 to 2000 mg,
preferably 250 to 2000 mg, more preferably 250 to 1650 mg,
more preferably still 400 to 1650 mg, especially 550 to 1000
mg. A suitable % w/w of the polysaccharide in a DRO of the
25 invention is 40 to 90% w/w, more preferably 60 to 80% w/w.

The above also is approximate to the total daily dosage
and can be achieved by one or more unit dosages taken once,
twice, three or more times daily. For example the total
30 daily dosage is typically 200 to 6000 mg, preferably having
a upper dosage limit of about 4000 mg and a lower limit of
about 400 mg.

The DRO formulation can be provided as an enteric
35 coated capsule containing the polysaccharide and having a
coating thickness and dissolution profile as described in
EP-A-0097651 (the contents of which are incorporated herein
by reference). Suitable coating include cellulose acetate

phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose or polyvinyl acetate phthalate but the preferred coating material is an anionic polymer, especially one having the dissolution profile specified in EP-A-0097651, optionally in admixture with a neutral insoluble but permeable polymer. The presently preferred anionic polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the anionic polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers such as poly(methacrylic acid, methyl methacrylate) in which the ratio of free acid groups to ester groups is about 1:1 (e.g. those available from Röhm-Pharma GmbH under the Trade Mark EUDRAGIT S). A neutral polymer coating, more specifically poly(ethylacrylate-methylmethacrylate) (e.g. Eudragit™ NE30D) may also be useful in some instances.

Examples of methacrylates (in the Eudragit™ range) for use as enteric coatings in accordance with the invention are as follows.

Chemical name	Trade name	CAS number
Poly(methacrylic acid, methyl methacrylate) 1:1	Eudragit™ L 100 Eudragit™ L 12.5 Eudragit™ L 12.5 P	[25806-15-1]
Poly(methacrylic acid, ethyl acrylate) 1:1	Eudragit™ L 30 D-55 Eudragit™ L 100-55	[25212-98-8]
Poly(methacrylic acid, methyl methacrylate) 1:2	Eudragit™ S 100 Eudragit™ S 12.5 Eudragit™ S 12.5 P	[25086-15-1]

In general coating thicknesses of about 25 to 200 µm, and especially 75 to 150 µm, are preferred using about 3 to 25 mg, preferably 8 to 15 mg of acidic coating material per

cm² of tablet or capsule surface. The precise coating thickness will however depend upon the solubility characteristics of the acidic material used and site to be treated.

In another preferred DRO or rectally administrable embodiment of the invention, sub 150µm particles of the polysaccharide or complex thereof (e.g. carbomer complex) is coated (partially or completely) or impregnated with a water insoluble anionic polymer. This prevents the formation of lumps and encourages the resulting hydrophobic particles of polysaccharide to disperse and coat the bowel wall when the contents of the DRO tablet or capsule are released. This technology is described in more detail in International Patent Application no. PCT/GB97/01847 (WO-A-9802573) (incorporated herein by reference).

By "sub 150µm particles", we mean such that 100% of particles in the DRO will pass through a 150 µm sieve. It is preferred that 100% of the hydrophilic carbomer particles pass a 100 µm sieve screen (i.e. they are sub 100 µm), more preferably at least 90%, especially at least 95%, of the hydrophilic particles pass a 63 µm sieve screen, more preferably a 50 µm sieve screen. The precise particle size must be small enough to provide a composition with a suitable degree of hydrophobicity following coating with the anionic polymer. Preferred particle size may vary according to the nature and amount of the cation present in the complex and the nature and amount of the anionic polymer.

The amount of anionic polymer used will depend upon the nature and amount of the cation present in the salt, the nature of the impregnating anionic polymer, and the degree of hydrophobicity required. A suitable amount can be determined by simple experimentation but usually the anionic polymer will be present in an amount of 10 to 50%, preferably 20 to 40, more preferably 25 to 35 and especially about one third, based on the weight of the carbomer

complex. Having regard to the small particle size, the amount of polymer will be less than the theoretical amount required to coat the particles, and the swelling and dissolution of the carbomer will not be controlled by pH.

The polysaccharide particles are impregnated/hydrophobised by milling and passing through a suitable sieve (as aforementioned), stirring the sieved particles into a mixture of e.g. isopropanol and water (solvent) and partly methyl esterified methacrylic acid polymer (e.g. Eudragit™ S100) at from 20 to 40% by weight of the polysaccharide particles (the solvent/coating solution having previously been agitated until clear), stirring and then evaporating the solvent under vacuum at about 50-70 °C to leave coated polysaccharide particles. Thereafter the resulting powder can be filled into gelatin capsules ready for enteric coating.

The invention will now be described by way of the following Examples.

Example 1.1 Enema with HPMC.

947.6 g of purified water is preserved with 2 g of methyl and 0.4 g propyl parabens. 50 g (dry basis) of HPMC (Methocel E) low viscosity grade (50 cP/mPa.s) is dissolved under mechanical stirring at room temperature. The solution is degassed (air) under reduced pressure in an oven. A clear viscous enema is obtained having pH 6.9, viscosity (spindle 64, 1.5 rpm - 20°C on Brookfield DV 11): 4,000 mPa.s. The formation is packed in a bag-in-can canister or in an enema plastic pouch or in a PE bottle all having a 100 g enema capacity delivery, thus delivering a full dose of 5,000 mg HPMC.

Example 2 : Foam Enema Formulation with Xanthan Gum.

14,871 g of purified water containing 22 g of dissolved methyl paraben and 2 g of dissolved propyl paraben as
5 preservatives were placed in a 20 litre Moltomat-Universal™
MMU 20 homogenizer. Then 435g of xanthan gum (Keltrol™ TF)
having a water content of 7.6% were dispersed in the
preserved water under efficient homogenization and reduced
pressure.

10

30 g of unbleached lecithin were then added and
dispersed under homogenization and reduced pressure. At
this stage the pH of the viscous gel obtained was 6.3. A
solution then made of 0.45 g sodium hydroxide pellets and 20
15 g of water was added and dispersed under reduced pressure.
The pH then was 6.93. Finally 155 g of Polysorbate 80 (non-
ionic surfactant) and 4 g of Citral (perfume) were added and
dispersed under reduced pressure.

20

The final foam enema appeared as a slightly hazy gel,
having a pH of 7.04 and a viscosity of 40,000 mPa.s at 20°C
as measured using a Brookfield DV II viscometer (1.5 rpm,
spindle 63).

25

A foam enema was then produced using this formulation
by adding 2.2 g of n-butane per 100 g of the above
formulation in a pressurised mixing unit and the mixture was
then filled into bag-in-can aerosol canisters. Each
canister contained 23 g of the mixture from which 21 g of
30 foam was delivered through a valve and an applicator, i.e.
about 530 mg of xanthan gum per delivered dose.

Example 3 : Liquid Enema Formulation with Xanthan Gum.

35

To 4,906 g of purified water containing 10 g of
dissolved methyl paraben and 2 g of dissolved propyl paraben
used as preservatives, 58.95 g of xanthan gum (Keltrol™ TF)
containing 6.7% water (i.e. 55 g dry basis) was added in an

homogenizer and dispersed under efficient homogenization under reduced pressure. The pH of the gel obtained was 6.05 and the viscosity was 7,500 mPa.s (22°C, 1.5 rpm-spindle 63 Brookfield DV II). At this stage 23 g of sodium citrate.

5 2H₂O was added as buffering agent. The pH went up to 7.15 and the viscosity was 40,000 mPa.s (measured as above). The formulation, which appears as a slightly hazy gel, was then packed into a bag-in-can canister equipped with a valve and an applicator and pressurised with nitrogen. If the bag of
10 the bag-in-can system is filled with 104 g of the formulation above then 100 g of the formulation can be delivered through the valve and applicator corresponding to a dose of 1.1 g of xanthan gum.

15 Example 4 : Treatment of Chronic Pouchitis

The enema of Example 2 was given to twenty adult patients who had previously undergone total colectomy with mucosal proctectomy and ileal J-pouch anal anastomosis for
20 ulcerative colitis and who had active chronic pouchitis refractory to standard therapy. The patients had chronic pouchitis, as defined as continuous symptoms of pouchitis for more than 4 weeks and a Pouchitis Disease Activity Index (PDAI) score of at least 7 points on an 18 point scale. All
25 patients had either failed or were intolerant to metronidazole as well as other commonly used treatments for pouchitis. Mucosal inflammation, determined by endoscopic examination, was limited to the pouch and did not extend into the ileum proximal to the pouch.

30

The demographics of the patients entered into the study are presented in Table 1. There were no significant differences in the age, gender distribution, smoking history, time since the diagnosis of ulcerative colitis,
35 duration of pouch function, time since the first episode of pouchitis, duration of the current episode of pouchitis, or in the medications previously used for treatment of pouchitis. All patients had been on medication for

pouchitis, previously, and one half of the patients were on concurrent treatment for chronic pouchitis (Table 2).

Three patients had to discontinue treatment because of
5 worsening of symptoms, but none developed dehydration or
required hospitalization. Three patients had cramping
discomfort in the pouch after taking the enema. One of the
patients who developed cramps discontinued treatment because
of the discomfort. One patient developed right lower
10 abdominal pain and the study medication was discontinued.

The initial or final endoscopic or histologic scores of
the patients are shown in Table 3.

TABLE 1

PATIENT CHARACTERISTICS

Number of Patients	20
Age (mean)	40 (18-62)
Number of Men:Women	13:7
Number of Cigarette Smokers, Current:Former:Never	1:2:17
Years since diagnosis of Ulcerative colitis. Median (range)	9 (3-32)
Months of pouch function. Median (range)	45 (4-161)
Months since the first episode of pouchitis. Median (range)	42 (3-151)
Months of current pouchitis episode. Median (range)	4 (0.8-151)

TABLE 2**THERAPY FOR POUCHITIS (20 PATIENTS)**

Therapy	No. Of Patients	
	Current	Previous
Antibiotics		
Metronidazole	3	16
Ciprofloxacin	6	15
Amoxicillin/clavulanic acid	1	6
Tetracycline	0	3
Trimethoprine/sulfamethoxazole	1	0
5-ASA		
Sulfasalazine	1	5
Oral mesalamine	0	5
Mesalamine enemas	0	3
Mesalamine suppositories	0	3
Corticosteroids		
Prednisone	1	7
Hydrocortisone enemas	0	5
Immune Modifiers		
Azathioprine	0	0
Cyclosporine	0	0
FK506	0	0
Antidiarrheals		
Loperamide	5	3
Codeine sulfate	0	1

TABLE 3DISEASE ACTIVITY AT BASELINE AND COMPLETION OF TREATMENT
WITH XANTHAN GUM ENEMA

5

	Baseline Median (range)	Completion Median (range)
Clinical Score	4 (1,5)	3 (0,4) *
Endoscopy Score	5 (1,6)	4 (1,6)
Histology Score	2 (2,6)	# 2 (2,6)
Total Score (PDAI)	11 (7,16)	9 (2,16) *

*p<0.5 for within-group change. Baseline vs completion (signed rank test with two missing values at completion filled in by overall (groups) Baseline values).

10

In conclusion, six of the twenty patients discontinued therapy and nine of fourteen patients (64%) who completed the treatment improved (defined as a reduction in the PDAI score of 3 points or more). This is particularly surprising in view of the fact that the patients were refractory to conventional therapy.

15

CLAIMS

1. A post-gastrically available delayed release oral (DRO) or rectally administrable pharmaceutical composition for the treatment or prophylaxis of IBD, said composition comprising a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in an amount effective to treat inflammatory bowel disease, together with a pharmaceutically acceptable carrier or vehicle.
2. A composition as claimed in Claim 1, wherein the polysaccharide is xanthan gum.
3. A composition as claimed in Claim 1, wherein the polysaccharide is HPMC
4. A composition as claimed in any one of the preceding claims, wherein the polysaccharide is present as the sole therapeutically active ingredient.
5. A DRO composition as claimed in any one of the preceding claims.
6. A DRO composition as claimed in Claim 5 which is an enteric coated dosage form adapted to release its contents within the region of the jejunum to the colon.
7. A rectally administrable composition as claimed in any one of Claims 1 to 4.
8. A rectally administrable composition as claimed in Claim 7 which is a liquid enema or foam enema.
9. A liquid enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 0.4 to 2 % w/w.

10. A foam enema as claimed in Claim 8, wherein the polysaccharide is xanthan gum in a concentration of 1.4 to 2.5 w/w.
- 5 11. A liquid enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 1 to 20 % w/w.
12. A foam enema as claimed in Claim 8, wherein the polysaccharide is HPMC in a concentration of 2.5 to 25 %
10 w/w.
13. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is xanthan gum in an amount of 400 to 2000 mg per unit dose.
15
14. A rectally administrable composition as claimed in Claim 7 or Claim 8, wherein the polysaccharide is HPMC in an amount of 1 to 20 g per unit dose..
- 20 15. A DRO composition as claimed in Claim 5 or Claim 6, wherein the unit dose of the polysaccharide is 400 to 2000 mg.
- 25 16. The use of a polysaccharide selected from xanthan gum and HPMC as a therapeutically active agent in the manufacture of a medicament for the treatment or prophylaxis of IBD.
- 30 17. A use as claimed in Claim 16, wherein the polysaccharide is the sole therapeutically active agent in the medicament.
18. A use as claimed in Claim 16 or Claim 17 wherein the disease state is pouchitis.
- 35 19. A use as claimed in Claim 16 or Claim 17 wherein the disease state is left-sided ulcerative colitis.

20. A use as claimed in Claim 16 or Claim 17 wherein the disease state is Crohn's Disease.

21. A use as claimed in any one of Claims 16 to 20, wherein
5 the medicament is a composition as defined in any one of Claims 1 to 15.

22. A method for the treatment or prophylaxis of IBD
comprising contacting the diseased mucosa of the gastro-
10 intestinal tract with a therapeutic amount of a polysaccharide selected from xanthan gum and HPMC.

INTERNATIONAL SEARCH REPORT

Internatio Application No
PCT/GB 98/02899

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/715 A61K9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 04136 A (DAY CHARLES E) 3 March 1994 see page 7, line 21 - line 26	1, 2, 16, 18-21
X, P	WO 98 01112 A (JENSFELT BIRGITTA ; ASTRA AB (SE)) 15 January 1998 see page 2, line 10 - page 3, line 3 see page 4; example 1	1, 3-5, 7, 8, 11, 12, 14-22
X	WO 92 16214 A (NORWICH EATON PHARMA) 1 October 1992 see page 308 see page 33; example 14	1-3, 5-8
X	WO 91 01129 A (HENNING BERLIN GMBH) 7 February 1991 see page 8 - page 12; examples 1-3, 6	1, 3, 7, 8, 11, 12, 14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 98/02899

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 03115 A (SLAGEL DAVID ; SACHETTO JEAN PIERRE (CH)) 8 February 1996 see page 12 - page 13; example 1	1,2,4, 7-10,13, 15
X	WO 96 30021 A (MAYO FOUNDATION) 3 October 1996 see page 4 - page 6; examples 1-3	1,2,5-8, 13,15
X	EP 0 517 274 A (CEDONA PHARM BV) 9 December 1992 see page 3; example 1	1,2,7-9, 13
X	FR 2 692 484 A (GOUCHET FRANCK) 24 December 1993 see page 3, line 15 - page 4, line 16 see page 5, line 21 - page 6, line 11	1,3,5,6
X	WO 96 40078 A (CIBUS PHARMACEUTICAL INC) 19 December 1996 see page 42 - page 43; example 4	1,3,5,15
X	CIFTCI K. ET AL: "Delivery of antitumor compounds to the rat colon: in vitro and in vivo evaluation" INT. J. PHARM., vol. 145, no. 1 2, 1996, pages 157-164, XP002092611 see page 158 - page 159	1,3,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9404136 A	03-03-1994	US 5380522 A AU 667955 B AU 4797893 A CA 2142016 A CN 1085084 A EP 0654992 A IL 106640 A	10-01-1995 18-04-1996 15-03-1994 03-03-1994 13-04-1994 31-05-1995 15-04-1997
WO 9801112 A	15-01-1998	AU 3470097 A	02-02-1998
WO 9216214 A	01-10-1992	AU 1577092 A AU 1587392 A WO 9216206 A	21-10-1992 21-10-1992 01-10-1992
WO 9101129 A	07-02-1991	DE 3924570 A AT 111731 T DE 59007260 D DK 436015 T EP 0436015 A ES 2058932 T JP 4501276 T US 5378470 A	31-01-1991 15-10-1994 27-10-1994 12-12-1994 10-07-1991 01-11-1994 05-03-1992 03-01-1995
WO 9603115 A	08-02-1996	AU 2988095 A BR 9508788 A CA 2195079 A CN 1158565 A CZ 9700171 A EP 0774957 A FI 970240 A HU 77528 A NO 970239 A NZ 289903 A PL 318315 A US 5759520 A	22-02-1996 25-11-1997 08-02-1996 03-09-1997 16-07-1997 28-05-1997 20-03-1997 28-05-1998 20-01-1997 28-10-1998 09-06-1997 02-06-1998
WO 9630021 A	03-10-1996	US 5691343 A AU 5421896 A CA 2216728 A CZ 9703092 A EP 0817634 A HU 9801241 A NO 974440 A NZ 306062 A PL 322526 A	25-11-1997 16-10-1996 03-10-1996 18-03-1998 14-01-1998 28-09-1998 25-09-1997 28-10-1998 02-02-1998
EP 0517274 A	09-12-1992	DE 4122337 A AT 121934 T AU 1907992 A CA 2110376 A CZ 9302663 A DE 59202096 D DK 586488 T WO 9221324 A EP 0586488 A ES 2074889 T HU 65898 A,B IE 68933 B	14-01-1993 15-05-1995 08-01-1993 10-12-1992 13-04-1994 08-06-1995 04-09-1995 10-12-1992 16-03-1994 16-09-1995 28-07-1994 24-07-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02899

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0517274 A		RU 2086241 C	10-08-1997
		SK 133793 A	11-05-1994
		US 5352681 A	04-10-1994
		ZA 9204111 A	15-11-1993
FR 2692484 A	24-12-1993	WO 9516451 A	22-06-1995
		AU 5702194 A	03-07-1995
WO 9640078 A	19-12-1996	US 5656294 A	12-08-1997
		US 5811388 A	22-09-1998
		AU 6163096 A	30-12-1996
		CA 2224170 A	19-12-1996
		EP 0831791 A	01-04-1998